Andersson EK, Strand M, Edlund K, Lindman K, Enquist P, Spjut S, Allard A, Elofsson M, Mei Y, Wadell G
Antimicrob. Agents Chemother. 54 (9) 3871-3877 [2010-09-00; online 2010-06-30]
Adenovirus infections are widespread in society and are occasionally associated with severe, but rarely with life-threatening, disease in otherwise healthy individuals. In contrast, adenovirus infections present a real threat to immunocompromised individuals and can result in disseminated and fatal disease. The number of patients undergoing immunosuppressive therapy for solid organ or hematopoietic stem cell transplantation is steadily increasing, as is the number of AIDS patients, and this makes the problem of adenovirus infections even more urgent to solve. There is no formally approved treatment of adenovirus infections today, and existing antiviral agents evaluated for their antiadenoviral effect give inconsistent results. We have developed a whole cell-based assay for high-throughput screening of potential antiadenoviral compounds. The assay is unique in that it is based on a replication-competent adenovirus type 11p green fluorescent protein (GFP)-expressing vector (RCAd11pGFP). This allows measurement of fluorescence changes as a direct result of RCAd11pGFP genome expression. Using this assay, we have screened 9,800 commercially available small organic compounds. Initially, we observed approximately 400 compounds that inhibited adenovirus expression in vitro by > or = 80%, but only 24 were later confirmed as dose-dependent inhibitors of adenovirus. One compound in particular, 2-{[2-(benzoylamino)benzoyl]amino}-benzoic acid, turned out to be a potent inhibitor of adenovirus replication.
Chemical Biology Consortium Sweden (CBCS) [Collaborative]
PubMed 20585112
DOI 10.1128/AAC.00203-10
Crossref 10.1128/AAC.00203-10
pii: AAC.00203-10
pmc: PMC2935025
Laboratories for Chemical Biology UmeƄ (LCBU)